

Alejandro Romero Martínez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/231113/publications.pdf>

Version: 2024-02-01

110
papers

3,624
citations

94433

37
h-index

149698

56
g-index

118
all docs

118
docs citations

118
times ranked

5509
citing authors

#	ARTICLE	IF	CITATIONS
1	Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?. Cellular and Molecular Neurobiology, 2022, 42, 489-500.	3.3	25
2	Influence of the extraction method on the recovery of bioactive phenolic compounds from food industry by-products. Food Chemistry, 2022, 378, 131918.	8.2	103
3	Alkylating Agent-Induced Toxicity and Melatonin-Based Therapies. Frontiers in Pharmacology, 2022, 13, 873197.	3.5	2
4	IMPLEMENTING CONTINUOUS ASSESSMENT IN TOXICOLOGY. INTED Proceedings, 2022, , .	0.0	0
5	Role of serendipity in the discovery of classical antidepressant drugs: Applying operational criteria and patterns of discovery. World Journal of Psychiatry, 2022, 12, 588-602.	2.7	5
6	Synthesis and Pharmacological Evaluation of New <i>N</i> -Sulfonylureas as NLRP3 Inflammasome Inhibitors: Identification of a Hit Compound to Treat Gout. Journal of Medicinal Chemistry, 2022, 65, 6250-6260.	6.4	10
7	In Silico Prediction of the Toxic Potential of Neuroprotective Bifunctional Molecules Based on Chiral <i>N</i> -Propargyl-1,2-amino Alcohol Derivatives. Chemical Research in Toxicology, 2021, 34, 1245-1249.	3.3	2
8	Toxicology of Blister Agents: Is Melatonin a Potential Therapeutic Option?. Diseases (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 462 T	2.5	9
9	The Coronavirus Disease 2019 (COVID-19): Key Emphasis on Melatonin Safety and Therapeutic Efficacy. Antioxidants, 2021, 10, 1152.	5.1	19
10	The crossroads of melatonin: Bibliometric analysis and mapping of global scientific research. Melatonin Research, 2021, 4, 152-172.	1.1	3
11	Detection of Neurological and Ophthalmological Pathologies with Optical Coherence Tomography Using Retinal Thickness Measurements: A Bibliometric Study. Applied Sciences (Switzerland), 2020, 10, 5477.	2.5	4
12	Melatonin Reduces NLRP3 Inflammasome Activation by Increasing $\hat{\pm}7$ nAChR-Mediated Autophagic Flux. Antioxidants, 2020, 9, 1299.	5.1	26
13	In Vitro and In Silico ADME-Tox Profiling and Safety Significance of Multifunctional Monoamine Oxidase Inhibitors Targeting Neurodegenerative Diseases. ACS Chemical Neuroscience, 2020, 11, 3793-3801.	3.5	7
14	Understanding the oncostatic actions displayed by melatonin in colorectal cancer therapy. Future Medicinal Chemistry, 2020, 12, 1201-1204.	2.3	6
15	Chemical weapons of mass destruction and terrorism: a threat analysis. , 2020, , 79-94.		2
16	Melatonin's efficacy in stroke patients; a matter of dose? A systematic review. Toxicology and Applied Pharmacology, 2020, 392, 114933.	2.8	15
17	Melatonin and neurodegeneration: From neurotoxic environment to cell resilience. Advances in Molecular Toxicology, 2020, 13, 69-108.	0.4	4
18	Impact of melatonin effects on toxicology of vesicant chemical warfare agents: When science meets reality. Melatonin Research, 2020, 3, 101-119.	1.1	2

#	ARTICLE	IF	CITATIONS
19	Highlights of ASS234: a novel and promising therapeutic agent for Alzheimer's disease therapy. <i>Neural Regeneration Research</i> , 2020, 15, 30.	3.0	10
20	ACQUIREMENT OF THEORETICAL KNOWLEDGE WITH PRACTICAL TOXICOLOGY. , 2020, , .		0
21	A SELF-LEARNING TOXICOLOGY EXPERIENCE. , 2020, , .		0
22	Potential of Melatonin as Adjuvant Therapy of Oral Cancer in the Era of Epigenomics. <i>Cancers</i> , 2019, 11, 1712.	3.7	21
23	QuinoxalineTacrine QT78, a Cholinesterase Inhibitor as a Potential Ligand for Alzheimer's Disease Therapy. <i>Molecules</i> , 2019, 24, 1503.	3.8	12
24	New flavonoid N,N-dibenzyl(N-methyl)amine hybrids: Multi-target-directed agents for Alzheimer's disease endowed with neurogenic properties. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2019, 34, 712-727.	5.2	27
25	The emergence of melatonin in oncology: Focus on colorectal cancer. <i>Medicinal Research Reviews</i> , 2019, 39, 2239-2285.	10.5	46
26	LEARNING TOXICOLOGY ON LINE. INTED Proceedings, 2019, , .	0.0	0
27	Analysis of gene expression profiles of CR80, a neuroprotective 1,8-Naphthyridine. <i>Future Medicinal Chemistry</i> , 2018, 10, 1289-1300.	2.3	4
28	Modulation of serine/threonine phosphatases by melatonin: therapeutic approaches in neurodegenerative diseases. <i>British Journal of Pharmacology</i> , 2018, 175, 3220-3229.	5.4	20
29	Melatonin: A hypothesis for Kawasaki disease treatment. <i>Medical Hypotheses</i> , 2018, 119, 6-10.	1.5	3
30	Neuroinflammation Signaling Modulated by ASS234, a Multitarget Small Molecule for Alzheimer's Disease Therapy. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2880-2885.	3.5	14
31	A History of the Pharmacological Treatment of Bipolar Disorder. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2143.	4.1	101
32	In silico assessment of the metabolism and its safety significance of multitarget propargylamine ASS234. <i>CNS Neuroscience and Therapeutics</i> , 2018, 24, 981-983.	3.9	2
33	Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2018, 156, 534-553.	5.5	38
34	Modulation of Heat Shock Response Proteins by ASS234, Targeted for Neurodegenerative Diseases Therapy. <i>Chemical Research in Toxicology</i> , 2018, 31, 839-842.	3.3	16
35	Recent Developments on Multi-Target-Directed Tacrines for Alzheimer's Disease. I. The Pyranotacrines. <i>Current Topics in Medicinal Chemistry</i> , 2018, 17, 3328-3335.	2.1	13
36	BENEFITS OF SELF-LEARNING BEFORE THE LECTURES. INTED Proceedings, 2018, , .	0.0	0

#	ARTICLE	IF	CITATIONS
37	RECREATING REAL CASES WITH VIRTUAL TOOLS IN RISK ASSESSMENT. , 2018, , .		0
38	Ischemic brain injury: New insights on the protective role of melatonin. <i>Free Radical Biology and Medicine</i> , 2017, 104, 32-53.	2.9	80
39	Neuroprotective effects of Eâ€PodoFavalinâ€15999 (AtremorineÂ®). <i>CNS Neuroscience and Therapeutics</i> , 2017, 23, 450-452.	3.9	15
40	5-Methyl-N-(8-(5,6,7,8-tetrahydroacridin-9-ylamino)octyl)-5H-indolo[2,3-b]quinolin-11-amine: a highly potent human cholinesterase inhibitor. <i>MedChemComm</i> , 2017, 8, 1307-1317.	3.4	10
41	Melatonin as a versatile molecule to design novel multitarget hybrids against neurodegeneration. <i>Future Medicinal Chemistry</i> , 2017, 9, 765-780.	2.3	21
42	Multipotente Liganden mit kombinierter Cholinesteraseâ€und Monoaminoxidaseâ€inhibition sowie Histaminâ€H ₃ Râ€Antagonismus bei neurodegenerativen Erkrankungen. <i>Angewandte Chemie</i> , 2017, 129, 12939-12943.	2.0	2
43	Multitargetâ€Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H ₃ Antagonism for Neurodegenerative Diseases. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 12765-12769.	13.8	83
44	Multitarget-Directed Antioxidants as Therapeutic Agents. , 2017, , 5-46.		4
45	Oxidative stress and gene expression profiling of cell death pathways in alpha-cypermethrin-treated SH-SY5Y cells. <i>Archives of Toxicology</i> , 2017, 91, 2151-2164.	4.2	42
46	The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease. <i>Journal of Psychiatry and Neuroscience</i> , 2017, 42, 59-69.	2.4	21
47	Melatonin and Nitrones As Potential Therapeutic Agents for Stroke. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 281.	3.4	7
48	ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy. <i>Frontiers in Neuroscience</i> , 2016, 10, 294.	2.8	58
49	Synthesis and biological evaluation of heterocyclic privileged medicinal structures containing (benz)imidazole unit. <i>Monatshefte FÃ¼r Chemie</i> , 2016, 147, 2209-2220.	1.8	16
50	New cinnamic â€ N-benzylpiperidine and cinnamic â€ N,N-dibenzyl(N-methyl)amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties. <i>European Journal of Medicinal Chemistry</i> , 2016, 121, 376-386.	5.5	46
51	Mycotoxins modify the barrier function of Caco-2 cells through differential gene expression of specific claudin isoforms: Protective effect of illite mineral clay. <i>Toxicology</i> , 2016, 353-354, 21-33.	4.2	80
52	Fipronil sulfone induced higher cytotoxicity than fipronil in SH-SY5Y cells: Protection by antioxidants. <i>Toxicology Letters</i> , 2016, 252, 42-49.	0.8	62
53	Permethrin-induced oxidative stress and toxicity and metabolism. A review. <i>Environmental Research</i> , 2016, 149, 86-104.	7.5	180
54	Melatonin as a Novel Therapeutic Agent Against Chemical Warfare Agents. , 2016, , 177-191.		0

#	ARTICLE	IF	CITATIONS
55	Therapeutic Potential of Melatonin in Combination with Other Drugs Against Neurodegeneration. , 2016, , 91-99.		0
56	Melatonin protects against oxygen and glucose deprivation by decreasing extracellular glutamate and Nox-derived ROS in rat hippocampal slices. NeuroToxicology, 2016, 57, 61-68.	3.0	33
57	Upregulation of Antioxidant Enzymes by <sc>ASS</sc>234, a Multitarget Directed Propargylamine for Alzheimer's Disease Therapy. CNS Neuroscience and Therapeutics, 2016, 22, 799-802.	3.9	11
58	The Antioxidant Additive Approach for Alzheimer's Disease Therapy: New Ferulic (Lipoic) Acid Plus Melatonin Modified Tacrines as Cholinesterases Inhibitors, Direct Antioxidants, and Nuclear Factor (Erythroid-Derived 2)-Like 2 Activators. Journal of Medicinal Chemistry, 2016, 59, 9967-9973.	6.4	83
59	Evidence for dose-additive effects of a type II pyrethroid mixture. In vitro assessment. Environmental Research, 2015, 138, 58-66.	7.5	35
60	Novel Tacrine-Graded Ugi Adducts as Multipotent Anti-Alzheimer Drugs: A Synthetic Renewal in Tacrine-Ferulic Acid Hybrids. ChemMedChem, 2015, 10, 523-539.	3.2	62
61	Development of Huper Tacrines as Non-Toxic, Cholinesterase Inhibitors for the Potential Treatment of Alzheimer's Disease. Mini-Reviews in Medicinal Chemistry, 2015, 15, 648-658.	2.4	12
62	Both Creatine and Its Product Phosphocreatine Reduce Oxidative Stress and Afford Neuroprotection in an <i>In Vitro</i> Parkinson's Model. ASN Neuro, 2014, 6, 175909141455494.	2.7	32
63	Wnt Signaling Pathway, a Potential Target for Alzheimer's Disease Treatment, is Activated by a Novel Multitarget Compound <sc>ASS</sc>234. CNS Neuroscience and Therapeutics, 2014, 20, 568-570.	3.9	19
64	Isoxazolotacrines as non-toxic and selective butyrylcholinesterase inhibitors for Alzheimer's disease. Future Medicinal Chemistry, 2014, 6, 1883-1891.	2.3	11
65	Dibenzo[1,4,5]thiadiazepine: A hardly-known heterocyclic system with neuroprotective properties of potential usefulness in the treatment of neurodegenerative diseases. European Journal of Medicinal Chemistry, 2014, 81, 350-358.	5.5	15
66	A review of metal-catalyzed molecular damage: protection by melatonin. Journal of Pineal Research, 2014, 56, 343-370.	7.4	145
67	Neuroprotective effect of dimebon against ischemic neuronal damage. Neuroscience, 2014, 267, 11-21.	2.3	10
68	Donepezil-Propargylamine-8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2014, 80, 543-561.	5.5	128
69	Melatonin as potential candidate to prevent the toxicity induced by chemical warfare agents. Archives of Toxicology, 2014, 88, 3-4.	4.2	34
70	The food contaminants aflatoxin B1, fumonisin B1, ocratoxina, T-2 toxin and deoxynivalenol decrease intestinal barrier permeability in human Caco-2 cells. Protector role of clay additives. Toxicology Letters, 2014, 229, S170.	0.8	0
71	ITH12410/SC058: A New Neuroprotective Compound with Potential in the Treatment of Alzheimer's Disease. ACS Chemical Neuroscience, 2014, 5, 770-775.	3.5	12
72	New Melatonin-N-Dibenzyl-N-methylamine Hybrids: Potent Neurogenic Agents with Antioxidant, Cholinergic, and Neuroprotective Properties as Innovative Drugs for Alzheimer's Disease. Journal of Medicinal Chemistry, 2014, 57, 3773-3785.	6.4	81

#	ARTICLE	IF	CITATIONS
73	In vitro relative potency of Type II pyrethroids and mixture dose-effects on oxidative stress cytotoxicity in SH-SY5Y, HepG2 and Caco-2 human cell lines. <i>Toxicology Letters</i> , 2014, 229, S45.	0.8	0
74	Toxicological and pharmacological evaluation, antioxidant, ADMET and molecular modeling of selected racemic chromenotacrine {11-amino-12-aryl-8,9,10,12-tetrahydro-7H-chromeno[2,3-b]quinolin-3-ols} for the potential prevention and treatment of Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2014, 74, 491-501.	5.5	44
75	Neuroprotective effect of melatonin against ischemia is partially mediated by alpha α 7 nicotinic receptor modulation and HO α 1 overexpression. <i>Journal of Pineal Research</i> , 2014, 56, 204-212.	7.4	93
76	Effect of natamycin on cytochrome P450 enzymes in rats. <i>Food and Chemical Toxicology</i> , 2013, 62, 281-284.	3.6	10
77	Toxicity induced by chemical warfare agents: Insights on the protective role of melatonin. <i>Chemico-Biological Interactions</i> , 2013, 206, 134-142.	4.0	12
78	In vitro assessment of adsorbents to prevent disruption of the intestinal barrier by mycotoxins. <i>Toxicology Letters</i> , 2013, 221, S149.	0.8	1
79	Novel multitarget ligand ITH33/IQM9.21 provides neuroprotection in in vitro and in vivo models related to brain ischemia. <i>Neuropharmacology</i> , 2013, 67, 403-411.	4.1	25
80	Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer's disease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 1916-1922.	2.2	134
81	Protective effect of creatine against 6-hydroxydopamine-induced cell death in human neuroblastoma SH-SY5Y cells: Involvement of intracellular signaling pathways. <i>Neuroscience</i> , 2013, 238, 185-194.	2.3	38
82	PP2A Ligand ITH12246 Protects against Memory Impairment and Focal Cerebral Ischemia in Mice. <i>ACS Chemical Neuroscience</i> , 2013, 4, 1267-1277.	3.5	20
83	Nontoxic and Neuroprotective β -Naphthotacrine for Alzheimer's Disease. <i>Chemical Research in Toxicology</i> , 2013, 26, 986-992.	3.3	33
84	Differential induction of cytochrome P450 isoforms and peroxisomal proliferation by cyfluthrin in male Wistar rats. <i>Toxicology Letters</i> , 2013, 220, 135-142.	0.8	20
85	Enantioselective Neuroprotective Effects of Tacipyryne ITH122 Against Oxygen and Glucose Deprivation in Rat Hippocampal Slices. <i>CNS Neuroscience and Therapeutics</i> , 2013, 19, 285-287.	3.9	4
86	Synthesis, biological assessment, and molecular modeling of racemic 7-aryl-9,10,11,12-tetrahydro-7H-benzo[7,8]chromeno[2,3-b]quinolin-8-amines as potential drugs for the treatment of Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2012, 54, 750-763.	5.5	66
87	Galantamine elicits neuroprotection by inhibiting iNOS, NADPH oxidase and ROS in hippocampal slices stressed with anoxia/reoxygenation. <i>Neuropharmacology</i> , 2012, 62, 1082-1090.	4.1	48
88	Cytotoxicity induced by deltamethrin and its metabolites in SH-SY5Y cells can be differentially prevented by selected antioxidants. <i>Toxicology in Vitro</i> , 2012, 26, 823-830.	2.4	63
89	Guanosine protects human neuroblastoma SH-SY5Y cells against mitochondrial oxidative stress by inducing heme oxygenase-1 via PI3K/Akt/GSK-3 β pathway. <i>Neurochemistry International</i> , 2012, 61, 397-404.	3.8	98
90	Long-term follow-up of hemodynamic responders to pharmacological therapy after variceal bleeding. <i>Hepatology</i> , 2012, 56, 706-714.	7.3	30

#	ARTICLE	IF	CITATIONS
91	Neurotoxicity induced by dexamethasone in the human neuroblastoma SH-SY5Y cell line can be prevented by folic acid. <i>Neuroscience</i> , 2011, 190, 346-353.	2.3	23
92	Calcium signalling mediated through $\alpha 7$ and non- $\alpha 7$ nAChR stimulation is differentially regulated in bovine chromaffin cells to induce catecholamine release. <i>British Journal of Pharmacology</i> , 2011, 162, 94-110.	5.4	27
93	Synthesis and pharmacological assessment of diversely substituted pyrazolo[3,4-b]quinoline, and benzo[b]pyrazolo[4,3-g][1,8]naphthyridine derivatives. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 4676-4681.	5.5	52
94	N-Acylaminophenothiazines: Neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 2224-2235.	5.5	46
95	Cholinergic and neuroprotective drugs for the treatment of Alzheimer and neuronal vascular diseases. II. Synthesis, biological assessment, and molecular modelling of new tacrine analogues from highly substituted 2-aminopyridine-3-carbonitriles. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 122-133.	3.0	44
96	Modulatory Effects of Melatonin on Cadmium-Induced Changes in Biogenic Amines in Rat Hypothalamus. <i>Neurotoxicity Research</i> , 2011, 20, 240-249.	2.7	18
97	Neuroprotective effect of guanosine against glutamate-induced cell death in rat hippocampal slices is mediated by the phosphatidylinositol 3 kinase/Akt/ glycogen synthase kinase 3 β pathway activation and inducible nitric oxide synthase inhibition. <i>Journal of Neuroscience Research</i> , 2011, 89, 1400-1408.	2.9	69
98	Neurotoxicity Induced by Okadaic Acid in the Human Neuroblastoma SH-SY5Y Line Can Be Differentially Prevented by $\alpha 7$ and $\alpha 2^*$ Nicotinic Stimulation. <i>Toxicological Sciences</i> , 2011, 123, 193-205.	3.1	44
99	Multipotent drugs with cholinergic and neuroprotective properties for the treatment of Alzheimer and neuronal vascular diseases. I. Synthesis, biological assessment, and molecular modeling of simple and readily available 2-aminopyridine-, and 2-chloropyridine-3,5-dicarbonitriles. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 5861-5872.	3.0	48
100	Poststress treatment with PNU282987 can rescue SH-SY5Y cells undergoing apoptosis via $\alpha 7$ nicotinic receptors linked to a Jak2/Akt/HO-1 signaling pathway. <i>Free Radical Biology and Medicine</i> , 2010, 49, 1815-1821.	2.9	75
101	Synergistic neuroprotective effect of combined low concentrations of galantamine and melatonin against oxidative stress in SH-SY5Y neuroblastoma cells. <i>Journal of Pineal Research</i> , 2010, 49, 141-148.	7.4	65
102	Synthesis, Inhibitory Activity of Cholinesterases, and Neuroprotective Profile of Novel 1,8-Naphthyridine Derivatives. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 5129-5143.	6.4	69
103	Effects of in utero and lactational exposure to endosulfan in prefrontal cortex of male rats. <i>Toxicology Letters</i> , 2008, 176, 58-67.	0.8	29
104	Relationship between blood concentrations of heavy metals and cytogenetic and endocrine parameters among subjects involved in cleaning coastal areas affected by the "Prestige" tanker oil spill. <i>Chemosphere</i> , 2008, 71, 447-455.	8.2	40
105	Toxic effects of cadmium on GABA and taurine content in different brain areas of adult male rats. <i>Journal of Physiology and Biochemistry</i> , 2005, 61, 439-446.	3.0	13
106	Toxic effects of cadmium on the regulatory mechanism of dopamine and serotonin on prolactin secretion in adult male rats. <i>Toxicology Letters</i> , 2005, 155, 87-96.	0.8	40
107	Cadmium exposure differentially modifies the circadian patterns of norepinephrine at the median eminence and plasma LH, FSH and testosterone levels. <i>Toxicology Letters</i> , 2004, 146, 175-182.	0.8	68
108	Effect of nitric oxide on prolactin secretion and hypothalamic biogenic amine contents. <i>Life Sciences</i> , 2004, 74, 1681-1690.	4.3	13

#	ARTICLE	IF	CITATIONS
109	Effect of cadmium on lymphocyte subsets distribution in thymus and spleen. Journal of Physiology and Biochemistry, 2003, 59, 43-48.	3.0	29
110	Effect of cadmium on 24-h variations in hypothalamic dopamine and serotonin metabolism in adult male rats. Experimental Brain Research, 2003, 149, 200-206.	1.5	47